Irofulven Phase 2 clinical study application approved by the Danish Medicines Agency and the Ethics Committee
Hoersholm, Denmark -- December 22th 2017 – Oncology Venture Sweden AB:s (OV:ST) (“Oncology Venture” or “OV”) has received approval for the application to run a phase 2 protocol of Irofulven for castration- and docetaxel resistant Prostate Cancer by the Danish Ethics Comitte and tha Danish Medicines Agency (DHMA). The study will include 13-27 patients selected for Irofulven benefit from DRP screened Swedish and Danish patients. The study will be run at two Danish sites – Swedish patients will be refered for Irofulven treatment at the University Hospital in Copenhagen. Using genomic